GRTX vs. BFRI, AKTX, ADIL, AEZS, ATHE, MTEM, LGVN, HEPA, MBRX, and VIRI
Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Biofrontera (BFRI), Akari Therapeutics (AKTX), Adial Pharmaceuticals (ADIL), Aeterna Zentaris (AEZS), Alterity Therapeutics (ATHE), Molecular Templates (MTEM), Longeveron (LGVN), Hepion Pharmaceuticals (HEPA), Moleculin Biotech (MBRX), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical preparations" industry.
Biofrontera (NASDAQ:BFRI) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends.
Galera Therapeutics has a net margin of 0.00% compared to Galera Therapeutics' net margin of -59.09%. Biofrontera's return on equity of 0.00% beat Galera Therapeutics' return on equity.
10.1% of Biofrontera shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 0.7% of Biofrontera shares are held by company insiders. Comparatively, 6.9% of Galera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Galera Therapeutics received 44 more outperform votes than Biofrontera when rated by MarketBeat users. However, 60.00% of users gave Biofrontera an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.
Biofrontera has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.
In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.
Biofrontera currently has a consensus price target of $18.00, suggesting a potential upside of 984.34%. Given Galera Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Biofrontera is more favorable than Galera Therapeutics.
Biofrontera has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.17, indicating that its share price is 117% more volatile than the S&P 500.
Summary
Biofrontera beats Galera Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Galera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galera Therapeutics Competitors List
Related Companies and Tools
